Shattuck Labs, Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a United States-based clinical-stage biotechnology company listed on the NASDAQ market in the United States. The company maintains offices in Austin, Texas and Durham, North Carolina, and has built its identity around immunology and inflammation-focused drug development. Founded in 2016, Shattuck originally developed its proprietary ARC (Agonist Redirected Checkpoint) platform and later streamlined its pipeline toward biologics that target tumor necrosis factor (TNF) superfamily pathways, especially the DR3/TL1A axis, with the goal of creating potentially first-in-class therapeutics for immune-mediated diseases. From an investment perspective, Shattuck is a small-cap biotech with a differentiated scientific profile rather than a diversified commercial franchise. Its core competitive advantage is deep expertise in TNF receptor biology, an area that can be challenging but potentially highly valuable in inflammatory and autoimmune disease research. The company’s current lead program is SL-325, a monoclonal DR3-blocking antibody being advanced in clinical development for inflammatory and immune-mediated indications. Shattuck reported in March 2026 that the Phase 1 trial of SL-325 is ongoing, with data expected in the second quarter of 2026, and that a Phase 2 study in Crohn’s disease is expected to begin in the third quarter of 2026. Shattuck’s history reflects the path of an innovation-driven biotech: it was founded by scientists and drug developers with expertise in immunobiology, took its public listing in 2020, and has since relied on capital markets and strategic financing to fund research and development. It does not yet have a commercial product portfolio generating meaningful revenue, so valuation is primarily driven by pipeline milestones, clinical readouts, and partnership potential. In 2025, the company completed an oversubscribed private placement of up to approximately $103 million, which materially strengthened its balance sheet and supported its current development plans. Shattuck also announced a collaboration with Ono Pharmaceutical, an important external validation of its platform and scientific direction. In competitive terms, Shattuck operates in a crowded but attractive biotech segment where large pharmaceutical companies and specialized immunology players are all pursuing differentiated mechanisms for autoimmune and inflammatory disorders. The company’s relative market position is that of a focused innovator: smaller in scale, but potentially high-upside if clinical data are positive. For investors in France, Belgium, and Switzerland, STTK should be viewed as a high-risk, event-driven NASDAQ biotech story. The most important near-term catalysts are clinical results for SL-325, the initiation of Crohn’s disease development, additional financing or partnership activity, and continued execution on its narrowed immunology strategy.